Statins in the treatment of chronic heart failure: Biological and clinical considerations

Cardiovascular Research

Volumn 71, Issue 3, 2006, Pages 443-454

  van der Harst, Pim ^a   Voors, Adriaan A ^a   van Gilst, Wiek H ^a   Böhm, Michael ^b   van Veldhuisen, Dirk J ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b SAARLAND UNIVERSITY   (Germany)

Author keywords

Cholesterol; Chronic heart failure; HMG CoA reductase inhibitors; Statins

Indexed keywords

ALDOSTERONE ANTAGONIST; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATORVASTATIN; BACTERIUM LIPOPOLYSACCHARIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN; CAPTOPRIL; CERIVASTATIN; CYTOKINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTOXIN; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 6; LIPOPROTEIN; LOSARTAN; MATRIX METALLOPROTEINASE; MEVALONIC ACID; MEVINOLIN; POLYUNSATURATED FATTY ACID; PRAVASTATIN; ROSUVASTATIN; SELENOPROTEIN; SIMVASTATIN; TUMOR NECROSIS FACTOR ALPHA; UBIQUINONE;

ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CAPILLARY DENSITY; CELL CULTURE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CORONARY ARTERY BLOOD FLOW; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; ENDOTOXEMIA; GRAM NEGATIVE INFECTION; HEART FAILURE; HEART FUNCTION; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE FIBROSIS; HEART MUSCLE ISCHEMIA; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPERTENSION; LIVER CIRRHOSIS; MORBIDITY; MORTALITY; MULTIVARIATE ANALYSIS; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RETROSPECTIVE STUDY; REVIEW; UNSPECIFIED SIDE EFFECT;

ANIMALS; CHOLESTEROL; HEART FAILURE, CONGESTIVE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS;

EID: 33746278413     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cardiores.2006.04.011     Document Type: Review

References (128)

1. Effects of pravastatin in patients with serum total cholesterol levels from 5.2 to 7.8 mmol/liter (200 to 300 mg/dl) plus two additional atherosclerotic risk factors. The Pravastatin Multinational Study Group for Cardiac Risk Patients. Am J Cardiol 72 (1993) 1031-1037
2. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344 (1994) 1383-1389
3. Shepherd J., Cobbe S.M., Ford I., Isles C.G., Lorimer A.R., Macfarlane P.W., et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 333 (1995) 1301-1308
4. Sacks F.M., Pfeffer M.A., Moye L.A., Rouleau J.L., Rutherford J.D., Cole T.G., et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 335 (1996) 1001-1009
5. Downs J.R., Clearfield M., Weis S., Whitney E., Shapiro D.R., Beere P.A., et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. JAMA 279 (1998) 1615-1622
6. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 339 (1998) 1349-1357
7. Schwartz G.G., Olsson A.G., Ezekowitz M.D., Ganz P., Oliver M.F., Waters D., et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL Study: a randomized controlled trial. JAMA 285 (2001) 1711-1718
8. MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360 (2002) 7-22
9. Serruys P.W., de Feyter P., Macaya C., Kokott N., Puel J., Vrolix M., et al. Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial. JAMA 287 (2002) 3215-3222
10. Shepherd J., Blauw G.J., Murphy M.B., Bollen E.L.E.M., Buckley B.M., Cobbe S.M., et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 360 (2002) 1623-1630
11. Athyros V.G. V. Treatment with atorvastatin to the National Cholesterol Educational Program goal versus 'usual' care in secondary coronary heart disease prevention. The GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study. Curr Med Res Opin 18 (2002) 220-228
12. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs. Usual care: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA 288 (2002) 2998-3007
13. Sever P.S., Dahlof B., Poulter N.R., Wedel H., Beevers G., Caulfield M., et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 361 (2003) 1149-1158
14. Holdaas H., Fellstrom B., Jardine A.G., Holme I., Nyberg G., Fauchald P., et al. Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial. Lancet 361 (2003) 2024-2031
15. Colhoun H.M., Betteridge D.J., Durrington P.N., Hitman G.A., Neil H.A., Livingstone S.J., et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 364 (2004) 685-696
16. Krum H., and McMurray J.J. Statins and chronic heart failure: do we need a large-scale outcome trial?. J Am Coll Cardiol 39 (2002) 1567-1573
17. Bohm M., Hjalmarson A., Kjekshus J., Laufs U., McMurray J., and Van Veldhuisen D.J. Heart failure and statins-Why do we need a clinical trial?. Z Kardiol 94 (2005) 223-230
18. Iribarren C. Cohort study of serum total cholesterol and in-hospital incidence of infectious diseases. Epidemiol Infect 121 (1998) 335-347
19. Pacelli F. Prognosis in intra-abdominal infections. Multivariate analysis on 604 patients. Arch Surg 131 (1996) 641-645
20. Onder G., Landi F., Volpato S., Fellin R., Carbonin P., Gambassi G., et al. Serum cholesterol levels and in-hospital mortality in the elderly. Am J Med 115 (2003) 265-271
21. Forette B. Cholesterol as risk factor for mortality in elderly women. Lancet 1 (1989) 868-870
22. Weverling-Rijnsburger A.W.E., Blauw G.J., Lagaay A.M., Knook D.L., Meinders A.E., and Westendorp R.G.J. Total cholesterol and risk of mortality in the oldest old. Lancet 350 (1997) 1119-1123
23. Corti M.C., Guralnik J.M., Salive M.E., Harris T., Ferrucci L., Glynn R.J., et al. Clarifying the Direct Relation between Total Cholesterol Levels and Death from Coronary Heart Disease in Older Persons. Ann Intern Med 126 (1997) 753-760
24. Schatz I.J., Masaki K., Yano K., Chen R., Rodriguez B.L., and Curb J.D. Cholesterol and all-cause mortality in elderly people from the Honolulu Heart Program: a cohort study. Lancet 358 (2001) 351-355
25. Kannel W.B. Epidemiology of heart failure. Am Heart J 121 (1991) 951-957
26. Hoffman R.M. Modifiable risk factors for incident heart failure in the coronary artery surgery study. Arch Intern Med 154 (1994) 417-423
27. Wilhelmsen L. Heart failure in the general population of men-morbidity, risk factors and prognosis. J Intern Med 249 (2001) 253-261
28. Coughlin S.S. Predictors of mortality from idiopathic dilated cardiomyopathy in 356,222 men screened for the Multiple Risk Factor Intervention Trial. Am J Epidemiol 139 (1994) 166-172
29. Kronmal R.A. Total serum cholesterol levels and mortality risk as a function of age. A report based on the Framingham data. Arch Intern Med 153 (1993) 1065-1073
30. Cowie M.R. The epidemiology of heart failure. Eur Heart J 18 (1997) 208-225
31. Vredevoe D.L., Woo M.A., Doering L.V., Brecht M.L., Hamilton M.A., and Fonarow G.C. Skin test anergy in advanced heart failure secondary to either ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 82 (1998) 323-328
32. Horwich T.B., Hamilton M.A., Maclellan W.R., and Fonarow G.C. Low serum total cholesterol is associated with marked increase in mortality in advanced heart failure. J Card Fail 8 (2002) 216-224
33. Mozaffarian D., Nye R., and Levy W.C. Statin therapy is associated with lower mortality among patients with severe heart failure. Am J Cardiol 93 (2004) 1124-1129
34. Rauchhaus M., Koloczek V., Volk H., Kemp M., Niebauer J., Francis D.P., et al. Inflammatory cytokines and the possible immunological role for lipoproteins in chronic heart failure. Int J Cardiol 76 (2000) 125-133
35. Rauchhaus M., Clark A.L., Doehner W., Davos C., Bolger A., Sharma R., et al. The relationship between cholesterol and survival in patients with chronic heart failure. J Am Coll Cardiol 42 (2003) 1933-1940
36. Richartz B.M., Radovancevic B., Frazier O.H., Vaughn W.K., and Taegtmeyer H. Low serum cholesterol levels predict high perioperative mortality in patients supported by a left-ventricular assist system. Cardiology 89 (1998) 184-188
37. Rosolova H., Cech J., Simon J., Spinar J., Jandova R., Widimsky sen J., et al. Short to long term mortality of patients hospitalised with heart failure in the Czech Republic{single bond}a report from the EuroHeart Failure Survey. Eur J Heart Fail 7 (2005) 780-783
38. Kalantar-Zadeh K., Block G., Horwich T., and Fonarow G.C. Reverse epidemiology of conventional cardiovascular risk factors in patients with chronic heart failure. J Am Coll Cardiol 43 (2004) 1439-1444
39. Riley M. Resting energy expenditure in chronic cardiac failure. Clin Sci (Lond) 80 (1991) 633-639
40. Anker S.D., Chua T.P., Ponikowski P., Harrington D., Swan J.W., Kox W.J., et al. Hormonal Changes and Catabolic/Anabolic Imbalance in Chronic Heart Failure and Their Importance for Cardiac Cachexia. Circulation 96 (1997) 526-534
41. Rauchhaus M., Coats A.J.S., and Anker S.D. The endotoxin-lipoprotein hypothesis. Lancet 356 (2000) 930-933
42. Niebauer J., Volk H.D., Kemp M., Dominguez M., Schumann R.R., Rauchhaus M., et al. Endotoxin and immune activation in chronic heart failure: a prospective cohort study. Lancet 353 (1999) 1838-1842
43. Netea M.G., Demacker P.N.M., Kullberg B.J., Boerman O.C., Verschueren I., Stalenhoef A.F.H., et al. Low-density lipoprotein receptor-deficient mice are protected against lethal endotoxemia and severe gram-negative infections. J Clin Invest 97 (1996) 1366-1372
44. Rundek T., Naini A., Sacco R., Coates K., and DiMauro S. Atorvastatin decreases the coenzyme Q10 level in the blood of patients at risk for cardiovascular disease and stroke. Arch Neurol 61 (2004) 889-892
45. Watts G.F. Plasma coenzyme Q (ubiquinone) concentrations in patients treated with simvastatin. J Clin Pathol 46 (1993) 1055-1057
46. Mortensen S.A., Leth A., Agner E., and Rohde M. Dose-related decrease of serum coenzyme Q10 during treatment with HMG-CoA reductase inhibitors. Mol Aspects Med 18 Suppl (1997) S137-S144
47. De Pinieux G. Lipid-lowering drugs and mitochondrial function: effects of HMG-CoA reductase inhibitors on serum ubiquinone and blood lactate/pyruvate ratio. Br J Clin Pharmacol 42 (1996) 333-337
48. Marz W., Siekmeier R., Muller H.M., Wieland H., Gross W., and Olbrich H.G. Effects of lovastatin and pravastatin on the survival of hamsters with inherited cardiomyopathy. J Cardiovasc Pharmacol Ther 5 (2000) 275-279
49. de Lorgeril M. Effects of lipid-lowering drugs on left ventricular function and exercise tolerance in dyslipidemic coronary patients. J Cardiovasc Pharmacol 33 (1999) 473-478
50. Permanetter B. Ubiquinone (coenzyme Q10) in the long-term treatment of idiopathic dilated cardiomyopathy. Eur Heart J 13 (1992) 1528-1533
51. Folkers K. Biochemical rationale and myocardial tissue data on the effective therapy of cardiomyopathy with coenzyme Q10. Proc Natl Acad Sci U S A 82 (1985) 901-904
52. Mortensen S.A. Overview on coenzyme Q10 as adjunctive therapy in chronic heart failure. Rationale, design and end-points of "Q-symbio"-a multinational trial. Biofactors 18 (2003) 79-89
53. Hatfield D.L., and Gladyshev V.N. How selenium has altered our understanding of the genetic code. Mol Cell Biol 22 (2002) 3565-3576
54. Dihanich M.E., Najarian D., Clark R., Gillman E.C., Martin N.C., and Hopper A.K. Isolation and characterization of MOD5, a gene required for isopentenylation of cytoplasmic and mitochondrial tRNAs of Saccharomyces cerevisiae. Mol Cell Biol 7 (1987) 177-184
55. Moosmann B., and Behl C. Selenoprotein synthesis and side-effects of statins. Lancet 363 (2004) 892-894
56. Warner G.J., Berry M.J., Moustafa M.E., Carlson B.A., Hatfield D.L., and Faust J.R. Inhibition of selenoprotein synthesis by selenocysteine tRNA[Ser]Sec lacking isopentenyladenosine. J Biol Chem 275 (2000) 28110-28119
57. Yokoyama I., Ohtake T., Momomura S., Nishikawa J., Sasaki Y., and Omata M. Reduced coronary flow reserve in hypercholesterolemic patients without overt coronary stenosis. Circulation 94 (1996) 3232-3238
58. Kaufmann P.A., Gnecchi-Ruscone T., Schafers K.P., Luscher T.F., and Camici P.G. Low density lipoprotein cholesterol and coronary microvascular dysfunction in hypercholesterolemia. J Am Coll Cardiol 36 (2000) 103-109
59. Baller D., Notohamiprodjo G., Gleichmann U., Holzinger J., Weise R., and Lehmann J. Improvement in coronary flow reserve determined by positron emission tomography after 6 months of cholesterol-lowering therapy in patients with early stages of coronary atherosclerosis. Circulation 99 (1999) 2871-2875
60. Guethlin M., Kasel A.M., Coppenrath K., Ziegler S., Delius W., and Schwaiger M. Delayed response of myocardial flow reserve to lipid-lowering therapy with fluvastatin. Circulation 99 (1999) 475-481
61. Mellwig K.P., Baller D., Gleichmann U., Moll D., Betker S., Weise R., et al. Improvement of coronary vasodilatation capacity through single LDL apheresis. Atherosclerosis 139 (1998) 173-178
62. Anversa P., Beghi C., Kikkawa Y., and Olivetti G. Myocardial infarction in rats. Infarct size, myocyte hypertrophy, and capillary growth. Circ Res 58 (1986) 26-37
63. Anversa P., Ricci R., and Olivetti G. Effects of exercise on the capillary vasculature of the rat heart. Circulation 75 (1987) I12-I18
64. Node K., Fujita M., Kitakaze M., Hori M., and Liao J.K. Short-term statin therapy improves cardiac function and symptoms in patients with idiopathic dilated cardiomyopathy. Circulation 108 (2003) 839-843
65. van der Harst P., Voors A.A., and Van Veldhuisen D.J. Short-term statin therapy and cardiac function and symptoms in patients with idiopathic dilated cardiomyopathy. Circulation 109 (2004) e34
66. Treasure C.B., Vita J.A., Cox D.A., Fish R.D., Gordon J.B., Mudge G.H., et al. Endothelium-dependent dilation of the coronary microvasculature is impaired in dilated cardiomyopathy. Circulation 81 (1990) 772-779
67. Chong A.Y., Blann A.D., Patel J., Freestone B., Hughes E., and Lip G.Y. Endothelial dysfunction and damage in congestive heart failure: relation of flow-mediated dilation to circulating endothelial cells, plasma indexes of endothelial damage, and brain natriuretic peptide. Circulation 110 (2004) 1794-1798
68. Katz S.D., Hryniewicz K., Hriljac I., Balidemaj K., Dimayuga C., Hudaihed A., et al. Vascular endothelial dysfunction and mortality risk in patients with chronic heart failure. Circulation 01 (2005)
69. Hornig B., Maier V., and Drexler H. Physical training improves endothelial function in patients with chronic heart failure. Circulation 93 (1996) 210-214
70. Rikitake Y., and Liao J.K. Rho GTPases, statins, and nitric oxide. Circ Res 97 (2005) 1232-1235
71. Anderson T.J., Meredith I.T., Yeung A.C., Frei B., Selwyn A.P., and Ganz P. The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion. N Engl J Med 332 (1995) 488-493
72. Treasure C.B., Klein J.L., Weintraub W.S., Talley J.D., Stillabower M.E., Kosinski A.S., et al. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. N Engl J Med 332 (1995) 481-487
73. Asselbergs F.W., van der Harst P., Jessurun G.A.J., Tio R.A., and van Gilst W.H. Clinical impact of vasomotor function assessment and the role of ACE-inhibitors and statins. Vascul Pharmacol 42 (2005) 125-140
74. van Boven A.J., Jukema J.W., Zwinderman A.H., Crijns H.J.G.M., Lie K.I., and Bruschke A.V.G. Reduction of transient myocardial ischemia with pravastatin in addition to the conventional treatment in patients with angina pectoris. Circulation 94 (1996) 1503-1505
75. Kureishi Y., Luo Z., Shiojima I., Bialik A., Fulton D., Lefer D.J., et al. The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nat Med 6 (2000) 1004-1010
76. Landmesser U., Engberding N., Bahlmann F.H., Schaefer A., Wiencke A., Heineke A., et al. Statin-induced improvement of endothelial progenitor cell mobilization, myocardial neovascularization, left ventricular function, and survival after experimental myocardial infarction requires endothelial nitric oxide synthase. Circulation 110 (2004) 1933-1939
77. Llevadot J., Murasawa S., Kureishi Y., Uchida S., Masuda H., Kawamoto A., et al. HMG-CoA reductase inhibitor mobilizes bone marrow-derived endothelial progenitor cells. J Clin Invest 108 (2001) 399-405
78. Vasa M., Fichtlscherer S., Adler K., Aicher A., Martin H., Zeiher A.M., et al. Increase in circulating endothelial progenitor cells by statin therapy in patients with stable coronary artery disease. Circulation 103 (2001) 2885-2890
79. Nickenig G., Baumer A.T., Temur Y., Kebben D., Jockenhovel F., and Bohm M. Statin-sensitive dysregulated AT1 receptor function and density in hypercholesterolemic men. Circulation 100 (1999) 2131-2134
80. De Boer R.A., Pinto Y.M., Suurmeijer A.J., Pokharel S., Scholtens E., Humler M., et al. Increased expression of cardiac angiotensin II type 1 (AT(1)) receptors decreases myocardial microvessel density after experimental myocardial infarction. Cardiovasc Res 57 (2003) 434-442
81. van der Harst P., Wagenaar L.J., Buikema H., Voors A.A., Plokker H.W., Morshuis W.J., et al. Effect of intensive versus moderate lipid lowering on endothelial function and vascular responsiveness to angiotensin ii in stable coronary artery disease. Am J Cardiol 96 (2005) 1361-1364
82. Maack C., Kartes T., Kilter H., Schafers H.J., Nickenig G., Bohm M., et al. Oxygen free radical release in human failing myocardium is associated with increased activity of Rac1-GTPase and represents a target for statin treatment. Circulation 108 (2003) 1567-1574
83. Saijonmaa O., Nyman T., Stewen P., and Fyhrquist F. Atorvastatin completely inhibits VEGF-induced ACE upregulation in human endothelial cells. Am J Physiol Heart Circ Physiol 286 (2004) H2096-H2102
84. Chen J. Inhibitory effect of candesartan and rosuvastatin on CD40 and MMPs expression in apo-E knockout mice: novel insights into the role of RAS and dyslipidemia in atherogenesis. J Cardiovasc Pharmacol 44 (2004) 446-452
85. Horiuchi M., Cui T.X., Li Z., Li J.M., Nakagami H., and Iwai M. Fluvastatin enhances the inhibitory effects of a selective angiotensin II Type 1 receptor blocker, valsartan, on vascular neointimal formation. Circulation 107 (2003) 106-112
86. Li Z., Iwai M., Wu L., Liu H.W., Chen R., Jinno T., et al. Fluvastatin enhances the inhibitory effects of a selective AT1 receptor blocker, valsartan, on atherosclerosis. Hypertension 44 (2004) 758-763
87. Koh K.K., Quon M.J., Han S.H., Chung W.J., Ahn J.Y., Seo Y.H., et al. Additive beneficial effects of losartan combined with simvastatin in the treatment of hypercholesterolemic, hypertensive patients. Circulation 110 (2004) 3687-3692
88. Ito M., Adachi T., Pimentel D.R., Ido Y., and Colucci W.S. Statins inhibit {beta}-adrenergic receptor-stimulated apoptosis in adult rat ventricular myocytes via a Rac1-dependent mechanism. Circulation 110 (2004) 412-418
89. Sugden P.H. Ras, Akt, and mechanotransduction in the cardiac myocyte. Circ Res 93 (2003) 1179-1192
90. Proud C.G. Ras, PI3-kinase and mTOR signaling in cardiac hypertrophy. Cardiovasc Res 63 (2004) 403-413
91. Liao J.K. Statin therapy for cardiac hypertrophy and heart failure. J Investig Med 52 (2004) 248-253
92. Dechend R. Amelioration of angiotensin II-induced cardiac injury by a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor. Circulation 104 (2001) 576-581
93. Takemoto M., Node K., Nakagami H., Liao Y., Grimm M., Takemoto Y., et al. Statins as antioxidant therapy for preventing cardiac myocyte hypertrophy. J Clin Invest 108 (2001) 1429-1437
94. Oi S. Lovastatin prevents angiotensin II-induced cardiac hypertrophy in cultured neonatal rat heart cells. Eur J Pharmacol 376 (1999) 139-148
95. Delbosc S., Cristol J.P., Descomps B., Mimran A., and Jover B. Simvastatin prevents angiotensin II-induced cardiac alteration and oxidative stress. Hypertension 40 (2002) 142-147
96. Luo J.D., Xie F., Zhang W.W., Ma X.D., Guan J.X., and Chen X. Simvastatin inhibits noradrenaline-induced hypertrophy of cultured neonatal rat cardiomyocytes. Br J Pharmacol 132 (2001) 159-164
97. Indolfi C., Di Lorenzo E., Perrino C., Stingone A.M., Curcio A., Torella D., et al. Hydroxymethylglutaryl coenzyme A reductase inhibitor simvastatin prevents cardiac hypertrophy induced by pressure overload and inhibits p21ras activation. Circulation 106 (2002) 2118-2124
98. Luo J.D., Zhang W.W., Zhang G.P., Guan J.X., and Chen X. Simvastatin inhibits cardiac hypertrophy and angiotensin-converting enzyme activity in rats with aortic stenosis. Clin Exp Pharmacol Physiol 26 (1999) 903-908
99. Su S.F., Hsiao C.L., Chu C.W., Lee B.C., and Lee T.M. Effects of pravastatin on left ventricular mass in patients with hyperlipidemia and essential hypertension. Am J Cardiol 86 (2000) 514-518
100. Jukema J.W., Bruschke A.V.G., van Boven A.J., Reiber J.H.C., Bal E.T., Zwinderman A.H., et al. Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels: the Regression Growth Evaluation Statin Study (REGRESS). Circulation 91 (1995) 2528-2540
101. Nissen S.E., Tuzcu E.M., Schoenhagen P., Brown B.G., Ganz P., Vogel R.A., et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA 291 (2004) 1071-1080
102. Lima J.A., Desai M.Y., Steen H., Warren W.P., Gautam S., and Lai S. Statin-induced cholesterol lowering and plaque regression after 6 months of magnetic resonance imaging-monitored therapy. Circulation 110 (2004) 2336-2341
103. Levine B. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med 323 (1990) 236-241
104. Kapadia S. The role of cytokines in the failing human heart. Cardiol Clin 16 (1998) 645
105. Blum A., and Miller H. Pathophysiological role of cytokines in congestive heart failure. Annu Rev Med 52 (2001) 15-27
106. Feldman A.M., Combes A., Wagner D., Kadakomi T., Kubota T., You Li Y., et al. The role of tumor necrosis factor in the pathophysiology of heart failure. J Am Coll Cardiol 35 (2000) 537-544
107. Ridker P.M., Rifai N., and Lowenthal S.P. Rapid reduction in c-reactive protein with cerivastatin among 785 patients with primary hypercholesterolemia. Circulation 103 (2001) 1191-1193
108. Ridker P.M., Cannon C.P., Morrow D., Rifai N., Rose L.M., McCabe C.H., et al. C-reactive protein levels and outcomes after statin therapy. N Engl J Med 352 (2005) 20-28
109. Holm T, Andreassen AK, Ueland T, Kjekshus J, Froland SS, Kjekshus E, et al., Effect of pravastatin on plasma markers of inflammation and peripheral endothelial function in male heart transplant recipients. Am J Cardiol 2001;87:815-8 [A9].
110. Spinale F.G., Coker M.L., Bond B.R., and Zellner J.L. Myocardial matrix degradation and metalloproteinase activation in the failing heart: a potential therapeutic target. Cardiovasc Res 46 (2000) 225-238
111. Bellosta S., Via D., Canavesi M., Pfister P., Fumagalli R., Paoletti R., et al. HMG-CoA reductase inhibitors reduce MMP-9 secretion by macrophages. Arterioscler Thromb Vasc Biol 18 (1998) 1671-1678
112. Furman C., Copin C., Kandoussi M., Davidson R., Moreau M., McTaggiart F., et al. Rosuvastatin reduces MMP-7 secretion by human monocyte-derived macrophages: potential relevance to atherosclerotic plaque stability. Atherosclerosis 174 (2004) 93-98
113. Li Y.Y., Feng Y.Q., Kadokami T., McTiernan C.F., Draviam R., Watkins S.C., et al. Myocardial extracellular matrix remodeling in transgenic mice overexpressing tumor necrosis factor alpha can be modulated by anti-tumor necrosis factor alpha therapy. Proc Natl Acad Sci U S A 97 (2000) 12746-12751
114. Bauersachs J., Galuppo P., Fraccarollo D., Christ M., and Ertl G. Improvement of left ventricular remodeling and function by hydroxymethylglutaryl coenzyme a reductase inhibition with cerivastatin in rats with heart failure after myocardial infarction. Circulation 104 (2001) 982-985
115. Hayashidani S., Tsutsui H., Shiomi T., Suematsu N., Kinugawa S., Ide T., et al. Fluvastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, attenuates left ventricular remodeling and failure after experimental myocardial infarction. Circulation 105 (2002) 868-873
116. Segal R., Pitt B., Poole-Wilson P., Sharma D., Bradstreet D.C., and Ikeda L.S. Effects of HMG-CoA reductase inhibitors (statins) in patients with heart failure. Eur J Heart Fail 2 Suppl 2 (2000) 96
117. Kjekshus J., Pedersen T.R., Olsson A.G., Faergeman O., and Pyorala K. The effects of simvastatin on the incidence of heart failure in patients with coronary heart disease. J Card Fail 3 (1997) 249-254
118. The effects of cholesterol lowering with simvastatin on cause-specific mortality and on cancer incidence in 20,536 high-risk people: a randomised placebo-controlled trial [ISRCTN48489393]. BMC Med 3 (2005) 6
119. Dickstein K., and Kjekshus J. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal trial in myocardial infarction with angiotensin II antagonist losartan. Lancet 360 (2002) 752-760
120. Hognestad A., Dickstein K., Myhre E., Snapinn S., and Kjekshus J. Effect of combined statin and beta-blocker treatment on one-year morbidity and mortality after acute myocardial infarction associated with heart failure. Am J Cardiol 93 (2004) 603-606
121. Laufs U., Wassmann S., Schackmann S., Heeschen C., Bohm M., and Nickenig G. Beneficial effects of statins in patients with non-ischemic heart failure. Z Kardiol 93 (2004) 103-108
122. Tousoulis D., Antoniades C., Bosinakou E., Kotsopoulou M., Tsioufis C., Tentolouris C., et al. Effects of atorvastatin on reactive hyperaemia and the thrombosis-fibrinolysis system in patients with heart failure. Heart 91 (2005) 27-31
123. Tousoulis D., Antoniades C., Bosinakou E., Kotsopoulou M., Pitsavos C., Vlachopoulos C., et al. Effects of atorvastatin on reactive hyperemia and inflammatory process in patients with congestive heart failure. Atherosclerosis 178 (2005) 359-363
124. LaRosa J.C., Grundy S.M., Waters D.D., Shear C., Barter P., Fruchart J.C., et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 352 (2005) 1425-1435
125. Kjekshus J., Dunselman P., Blideskog M., Eskilson C., Hjalmarson A., McMurray J.V., et al. A statin in the treatment of heart failure? Controlled rosuvastatin multinational study in heart failure (CORONA): study design and baseline characteristics. Eur J Heart Fail 7 (2005) 1059-1069
126. Tavazzi L., Tognoni G., Franzosi M.G., Latini R., Maggioni A.P., Marchioli R., et al. Rationale and design of the GISSI heart failure trial: a large trial to assess the effects of n-3 polyunsaturated fatty acids and rosuvastatin in symptomatic congestive heart failure. Eur J Heart Fail 6 (2004) 635-641
127. Landmesser U., Bahlmann F., Mueller M., Spiekermann S., Kirchhoff N., Schulz S., et al. Simvastatin versus ezetimibe: pleiotropic and lipid-lowering effects on endothelial function in humans. Circulation 111 (2005) 2356-2363
128. Shepherd J., Blauw G.J., Murphy M.B., Cobbe S.M., Bollen E.L.E.M., Buckley B.M., et al. The design of a prospective study of pravastatin in the elderly at risk (PROSPER). Am J Cardiol 84 (1999) 1192-1197